RECRUITING

Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be cured: mostly those with recurrence in one single organ. Brain metastases are rare after esophagectomy for cancer, but they have a serious impact on survival. Agressive treatment is often moren difficult for brain metastases compared to other metastases and some risk factors have been identified earlier. There is an impression that the incidence of brain metastases in esophageal cancer patients has increased since the introduction of neoadjuvant treatment schemes. However, this is not clear yet. A potential explanation could be that chemotherapy disturbs the blood-brain-barrier, hereby facilitating the migration of tumor cells to the brain. The purpose of this study is to retrospectively analyze the incidence and potential risk factors of brain metastases in patients who underwent esophagectomy for esophageal cancer. Patients treated between 2000 and 2019 will be included and outcome parameters are Odds Ratio for brain metastases (comparison between primary surgery and neoadjuvant treatment followed by surgery), time to recurrence and risk factors, number and characteristics of the brain metastases.

Official Title

Risk Factors and Treatment Options for Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer: a Multicentric Retrospective Cohort Study (METABREC)

Quick Facts

Study Start:2020-06-02
Study Completion:2025-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04654975

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients receiving surgical treatment for esophageal cancer between 1 januari 2000 and 31 december 2019
  2. * All types of neoadjuvant treatment followed by surgery, primary surgery or salvage surgery.
  3. * Adenocarcinoma or squamous cell carcinoma histology
  1. * other histology type than adenocarcinoma or squamous cell carcinoma
  2. * Hypopharyngeal carcinoma extending to the esophagus (requiring total laryngo-pharyngo-esophagectomy)
  3. * Early esophageal carcinoma (cT IS-1a N0 M0)
  4. * palliative esophagectomy

Contacts and Locations

Study Contact

Lieven P Depypere, PhD
CONTACT
+32 16 346820
lieven.depypere@uzleuven.be
Johnny Moons, Msc
CONTACT
+32 16 346820
johnny.moons@uzleuven.be

Principal Investigator

Lieven P Depypere, PhD
PRINCIPAL_INVESTIGATOR
UZ Leuven

Study Locations (Sites)

MD Anderson Cancer Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: Universitaire Ziekenhuizen KU Leuven

  • Lieven P Depypere, PhD, PRINCIPAL_INVESTIGATOR, UZ Leuven

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-06-02
Study Completion Date2025-03-31

Study Record Updates

Study Start Date2020-06-02
Study Completion Date2025-03-31

Terms related to this study

Additional Relevant MeSH Terms

  • Esophageal Neoplasms
  • Esophagectomy
  • Brain Metastases